Prevalence of Liver Dysfunction in Pediatric Patients With Congenital Heart Disease at Assiut.

Sponsor
Assiut University
Study ID
NCT07144501
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Congenital Heart Disease
  • Liver Dysfunction

Eligibility Criteria

Sex
ALL
Age
N/A - 16 Years
Healthy Volunteers
Not accepted

Interventions

  • Ultrasonography — DIAGNOSTIC_TEST
    Ultrasound, also known as sonography or ultrasonography, is a medical imaging technique that uses high-frequency sound waves to create real-time images of internal body structures
  • Blood Sampling — PROCEDURE
    To assess hepatic function in congenital heart disease (CHD) patients, blood samples will be collected from all patients in our study for: * Alanine Transferase (ALT). * Aspartate Aminotransferase (AST). * Gamma Glutamyl Transferase (GGT). * Alkaline Phosphatase (ALP). * Total/direct bilirubin. * Albumin. * Prothrombin time. * International Normalized Ratio (INR). * Platelet count.

Study Details

Liver dysfunction is a well-documented complication in patients with congenital heart disease (CHD). The mechanisms leading to hepatic dysfunction may be multifactorial. Key risk factors for liver dysfunction in CHD include prolonged hypoxemia, high venous pressure, and prolonged duration of heart disease. While global studies have extensively explored this association, the prevalence of liver dysfunction in CHD varies, with studies reporting hepatic fibrosis in 30-40% of Fontan patients, while regional data, particularly from Egypt, remain limited. In this research we aim to determine the prevalence of biochemical and radiological hepatic abnormalities in pediatric CHD patients attending Assiut University Children's Hospital.

Key Dates

First listed
Aug 27, 2025
Start date
Sep 15, 2025
Status verified
Aug 2025
Primary completion
Feb 15, 2026
Completion
Mar 15, 2026

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING

Arms

  • Experimental: CHD patients
    A- Full History Taking: B- General Examination: C- Cardiac Examination: 1. Physical examination 2. Echocardiography D- Hepatic Examination: 1. Physical examination 2. Biochemical Markers: To assess hepatic function in congenital heart disease (CHD) patients, blood samples will be collected from all patients in our study 3. Abdominal ultrasound:

Primary Outcome Measure

To assess the prevalence of hepatic dysfunction among CHD [ Time Frame: 5 months ]

Central Contacts

Related Studies